Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock Has Consensus Price Target of $10.25

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have earned a consensus recommendation of “Moderate Buy” from the seventeen analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $10.25.

A number of brokerages recently commented on CMPX. Citigroup reiterated a “market outperform” rating on shares of Compass Therapeutics in a research report on Wednesday, September 23rd. Wedbush set a $4.00 target price on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Compass Therapeutics in a research report on Wednesday, September 23rd. Piper Sandler boosted their price target on shares of Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Lifesci Capital lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 22nd.

Compass Therapeutics Stock Performance

NASDAQ CMPX opened at $0.76 on Thursday. The stock has a fifty day moving average of $1.36 and a 200-day moving average of $3.15. The stock has a market capitalization of $137.35 million, a P/E ratio of -1.91 and a beta of 1.06. Compass Therapeutics has a 52 week low of $0.73 and a 52 week high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities research analysts forecast that Compass Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Trading of Compass Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Compass Therapeutics in the 2nd quarter valued at about $24,707,000. Palo Alto Investors LP acquired a new stake in shares of Compass Therapeutics in the 2nd quarter valued at approximately $12,771,670. Squarepoint Ops LLC boosted its stake in Compass Therapeutics by 1,906.9% during the 2nd quarter. Squarepoint Ops LLC now owns 1,007,507 shares of the company’s stock worth $2,206,000 after acquiring an additional 957,305 shares during the last quarter. Bank of America Corp DE boosted its stake in Compass Therapeutics by 224.9% during the 1st quarter. Bank of America Corp DE now owns 865,613 shares of the company’s stock worth $4,579,000 after acquiring an additional 599,179 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Compass Therapeutics during the 2nd quarter worth approximately $1,147,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.